Suppr超能文献

-5/del(5q) 或 -7/del(7q) 相关急性髓系白血病中长链非编码 RNA 竞争相互作用的鉴定和六甲基化基因预后特征。

Identification of distinctive long noncoding RNA competitive interactions and a six-methylated-gene prognostic signature in acute myeloid leukemia with -5/del(5q) or -7/del(7q).

机构信息

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, China.

出版信息

J Cell Biochem. 2020 Feb;121(2):1563-1574. doi: 10.1002/jcb.29391. Epub 2019 Sep 18.

Abstract

BACKGROUND

Acute myeloid leukemia (AML) with -5/del(5q) or -7/del(7q) has special clinical and biological characteristics, but its molecular mechanisms and risk stratification remain unknown.

METHODS

The RNA sequencing and DNA methylation of 23 patients with -5/del(5q) or -7/del(7q) and 128 patients with other subtypes of acute myeloid leukemia were obtained from The Cancer Genome Atlas (TCGA). The regulatory mechanisms of competitive endogenous RNA (ceRNA) network and DNA methylation on gene expression were explored. To find robust and specific risk stratification for this AML subtype, a prognostic model was established and evaluated through four independent data sets.

RESULTS

We identified 966 differentially expressed long noncoding RNA, 2274 differentially expressed genes, and 47 differentially expressed microRNAs, and constructed a ceRNA network. After the integrated analysis of differentially methylated and expressed genes, 19 genes showed the opposite trend between the methylation variation and gene expression. An six-methylated-gene prognostic signature which highly correlated with overall survival was established, and the performance was validated by leave-one-out cross validation method and permutation test. Furthermore, the excellent prognostic value of this model was supported by an independent cohort, while specificity of this model was validated by three independent data sets, suggesting it as a predictive classifier with high efficiency for distinguishing those with -5/del(5q) or -7/del(7q) from other AML subtypes.

CONCLUSIONS

The ceRNA network may provide new ideas for the diagnosis and treatment for patients with -5/del(5q) or -7/del(7q).The six-methylated-gene prognostic signature was a robust, specific, and clinically practical risk stratification for the outcome of patients with AML having -5/del(5q) or -7/del(7q).

摘要

背景

具有 -5/del(5q) 或 -7/del(7q) 的急性髓系白血病(AML)具有特殊的临床和生物学特征,但其分子机制和风险分层仍不清楚。

方法

从癌症基因组图谱(TCGA)获得了 23 例 -5/del(5q) 或 -7/del(7q) 患者和 128 例其他亚型急性髓系白血病患者的 RNA 测序和 DNA 甲基化数据。探索了竞争内源性 RNA(ceRNA)网络和 DNA 甲基化对基因表达的调控机制。为了为这种 AML 亚型找到稳健且特异的风险分层,通过四个独立数据集建立并评估了一个预后模型。

结果

我们鉴定了 966 个差异表达的长非编码 RNA、2274 个差异表达基因和 47 个差异表达 microRNA,并构建了 ceRNA 网络。在对差异甲基化和表达基因进行综合分析后,有 19 个基因的甲基化变化和基因表达之间呈现相反的趋势。建立了一个与总生存期高度相关的六甲基化基因预后标志,并通过留一法交叉验证和置换检验验证了其性能。此外,该模型在独立队列中得到了很好的验证,在另外三个独立数据集的验证中也验证了其特异性,这表明它是一种高效的预测分类器,可以区分具有 -5/del(5q) 或 -7/del(7q) 的患者和其他 AML 亚型。

结论

ceRNA 网络可能为 -5/del(5q) 或 -7/del(7q) 患者的诊断和治疗提供新的思路。六甲基化基因预后标志是一种稳健、特异且临床上实用的风险分层方法,可用于预测具有 -5/del(5q) 或 -7/del(7q) 的 AML 患者的预后。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验